The non-sRCCs were predominantly higher risk tumours; only 14 of the 268 (5%) had Hippo pathway alterations, involving NF2 (6/268), FAT1 (3/268), LATS1 (2/268), LATS2 (3/268) and YAP1 (1/268). Here, NF2 is linked to neoplasm.